Table 1.

Baseline Characteristics of Included Studies for the Primary Analysis

StudyYearRandomized TreatmentTotal No. in Original StudyFollow-Up Time, dLVEF (%)Creatinine, mg/dLeGFR, mL/min per 1.73 m2Concomitant Therapy, %Medical History, %Baseline Vitals
ACEiARBBBLMRALoop DiureticDigoxinAFHTDMIschemicSBP, mm HgDBP, mm HgHR, bpm
 Angiotensin-converting enzyme inhibitors (ACEi)
 Angiotensin II receptor blockers (ARB)
 Mineralocorticoid receptor antagonists (MRA)
 Angiotensin II receptor blockers (ARB)
  • * Total number of patients from renal substudy as the definition of HFREF/HFPEF was different in the main trial program. AF indicates atrial fibrillation; BBL, β-blocker; CHARM, Candesartan in Heart Failure-Assessment of Reduction in Mortality and Morbidity; DBP, diastolic blood pressure; DM, diabetes mellitus; eGFR, estimated glomerular filtration rate; EMPHASIS-HF, Eplerenone in Mild Patients Hospitalization and Survival Study in Heart Failure; EPHESUS, Eplerenone Post-Acute Myocardial Infarction Heart Failure Efficacy and Survival Study; HT, hypertension; I-Preserve, Irbesartan in Heart Failure With Preserved Ejection Fraction Study; LVEF, left ventricular ejection fraction; RALES, Randomized Aldactone Evaluation Study; SAVE, Survival and Ventricular Enlargement; SOLVD, Studies of Left Ventricular Dysfunction; SBP, systolic blood pressure; and Val-HeFT, Valsartan Heart Failure Trial.